Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07043803 · ClinicalTrials.gov registry record · NA

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

A NA study of Bipolar Disorder and Schizoaffective Disorder, sponsored by University of Pittsburgh.

Recruiting
Registry status
NA
Development phase
111
Enrollment target
4
Study locations

NCT07043803 is a NA study of Bipolar Disorder and Schizoaffective Disorder that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 111 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07043803, a NA study of Bipolar Disorder and Schizoaffective Disorder, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
NA
Development phase
111 participants
Enrollment target
4
Study locations

Study Summary

The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.

Interventions

  • OTHER Reduction of anticholinergic medication

Study Locations (4)

Pennsylvania

  • Western Behavioral Health of the Alleghenies - Altoona
  • UPMC Western Behavioral Health at Safe Harbor - Erie
  • Western Behavioral Health Mon Yough - McKeesport
  • Comprehensive Recovery Services (Pittsburgh) of Western Psychiatric Hospital, Ambulatory Clinics and Residential Programs - UPMC, Pittsburgh, PA - Pittsburgh

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2025-07-16
Est. Completion 2026-05
Phase NA

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT07043803

The ClinicalTrials.gov registry entry for NCT07043803 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (67% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Reduction of anticholinergic medication is the first listed.

NCT07043803 reports 4 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07043803 about?

NCT07043803 is a clinical study titled "Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders". The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.

What is the current status of trial NCT07043803?

This trial is currently recruiting. It is a NA study. The enrollment target is 111 participants. The study started on 2025-07-16. Estimated completion is 2026-05.

What conditions does trial NCT07043803 study?

This clinical trial studies the following conditions: Bipolar Disorder, Schizoaffective Disorder, Psychiatric Disorders, Schizophenia Disorder.

What interventions are being tested in trial NCT07043803?

The interventions under investigation include: Reduction of anticholinergic medication (OTHER).

Who is sponsoring clinical trial NCT07043803?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07043803 being conducted?

This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.